News & Views - Page 24 of 53 - Telix Pharmaceuticals Limited

Telix Quarterly Shareholder Update – CEO Presentation and Transcript of Investor Conference Call

Telix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with investors.

Activity Report and Sales Note to Accompany Appendix 4C

Telix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging product

AGM Notice of Meeting – Telix Pharmaceuticals Limited

Telix Pharmaceuticals provides notice of The Annual General Meeting of the Shareholders on Tuesday 12 May 2020

Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic

Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has entered into a commercial agreement with Cardinal Health

Telix Completes Acquisition of European Radiopharmaceutical Production Facility

Telix is pleased to announce it has now completed the acquisition of a licensed radiopharmaceutical production facility in Seneffe, Belgium

Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC

Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer drugs

Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)

Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its submission of an NDA for TLX591-CDx

Telix Pharmaceuticals Releases Annual Report Year Ending 2019

Telix Pharmaceuticals Limited Releases Annual Report Year Ending 2019.

Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer

Telix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s Molecularly Targeted Radiation (MTR) intellectual property for the treatment of non-muscle invasive bladder cancer that is resistant to standard therapies.

Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer

Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the treatment of ovarian and lung cancers.